Literature DB >> 21061851

Dopaminergic regulation of sleep and cataplexy in a murine model of narcolepsy.

Christian R Burgess1, Gavin Tse, Lauren Gillis, John H Peever.   

Abstract

STUDY
OBJECTIVES: To determine if the dopaminergic system modulates cataplexy, sleep attacks and sleep-wake behavior in narcoleptic mice.
DESIGN: Hypocretin/orexin knockout (i.e., narcoleptic) and wild-type mice were administered amphetamine and specific dopamine receptor modulators to determine their effects on sleep, cataplexy and sleep attacks. PATIENTS OR PARTICIPANTS: Hypocretin knockout (n = 17) and wild-type mice (n = 21).
INTERVENTIONS: Cataplexy, sleep attacks and sleep-wake behavior were identified using electroencephalogram, electromyogram and videography. These behaviors were monitored for 4 hours after an i.p. injection of saline, amphetamine and specific dopamine receptor modulators (D1- and D2-like receptor modulators). MEASUREMENTS AND
RESULTS: Amphetamine (2 mg/kg), which increases brain dopamine levels, decreased sleep attacks and cataplexy by 61% and 67%, suggesting that dopamine transmission modulates such behaviors. Dopamine receptor modulation also had powerful effects on sleep attacks and cataplexy. Activation (SKF 38393; 20 mg/kg) and blockade (SCH 23390; 1 mg/kg) of D1-like receptors decreased and increased sleep attacks by 77% and 88%, without affecting cataplexy. Pharmacological activation of D2-like receptors (quinpirole; 0.5 mg/kg) increased cataplectic attacks by 172% and blockade of these receptors (eticlopride; 1 mg/kg) potently suppressed them by 97%. Manipulation of D2-like receptors did not affect sleep attacks.
CONCLUSIONS: We show that the dopaminergic system plays a role in regulating both cataplexy and sleep attacks in narcoleptic mice. We found that cataplexy is modulated by a D2-like receptor mechanism, whereas dopamine modulates sleep attacks by a D1-like receptor mechanism. These results support a role for the dopamine system in regulating sleep attacks and cataplexy in a murine model of narcolepsy.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21061851      PMCID: PMC2941415          DOI: 10.1093/sleep/33.10.1295

Source DB:  PubMed          Journal:  Sleep        ISSN: 0161-8105            Impact factor:   5.849


  61 in total

1.  Dopaminergic role in stimulant-induced wakefulness.

Authors:  J P Wisor; S Nishino; I Sora; G H Uhl; E Mignot; D M Edgar
Journal:  J Neurosci       Date:  2001-03-01       Impact factor: 6.167

2.  Increased dopaminergic transmission mediates the wake-promoting effects of CNS stimulants.

Authors:  S Nishino; J Mao; R Sampathkumaran; J Shelton
Journal:  Sleep Res Online       Date:  1998

3.  Orexin neurons are directly and indirectly regulated by catecholamines in a complex manner.

Authors:  Akihiro Yamanaka; Yo Muraki; Kanako Ichiki; Natsuko Tsujino; Thomas S Kilduff; Katsutoshi Goto; Takeshi Sakurai
Journal:  J Neurophysiol       Date:  2006-04-12       Impact factor: 2.714

4.  Behavioral state instability in orexin knock-out mice.

Authors:  Takatoshi Mochizuki; Amanda Crocker; Sarah McCormack; Masashi Yanagisawa; Takeshi Sakurai; Thomas E Scammell
Journal:  J Neurosci       Date:  2004-07-14       Impact factor: 6.167

5.  Activity of dorsal raphe cells across the sleep-waking cycle and during cataplexy in narcoleptic dogs.

Authors:  M-F Wu; J John; L N Boehmer; D Yau; G B Nguyen; J M Siegel
Journal:  J Physiol       Date:  2004-01-01       Impact factor: 5.182

6.  The roles of midbrain and diencephalic dopamine cell groups in the regulation of cataplexy in narcoleptic Dobermans.

Authors:  Mutsumi Okura; Nobuhiro Fujiki; Ichiro Kita; Kazuki Honda; Yasushi Yoshida; Emmanuel Mignot; Seiji Nishino
Journal:  Neurobiol Dis       Date:  2004-06       Impact factor: 5.996

7.  In vivo evidence for the existence of autoreceptors on dopaminergic, serotonergic, and cholinergic neurons in the brain.

Authors:  B H Westerink; P De Boer; W Timmerman; J B De Vries
Journal:  Ann N Y Acad Sci       Date:  1990       Impact factor: 5.691

Review 8.  Narcolepsy and the hypocretin system--where motion meets emotion.

Authors:  Jerome M Siegel; Lisa N Boehmer
Journal:  Nat Clin Pract Neurol       Date:  2006-10

9.  Cholinergic mechanisms in canine narcolepsy--I. Modulation of cataplexy via local drug administration into the pontine reticular formation.

Authors:  M S Reid; M Tafti; J N Geary; S Nishino; J M Siegel; W C Dement; E Mignot
Journal:  Neuroscience       Date:  1994-04       Impact factor: 3.708

10.  Hypocretin (orexin) cell loss in Parkinson's disease.

Authors:  Thomas C Thannickal; Yuan-Yang Lai; Jerome M Siegel
Journal:  Brain       Date:  2007-05-09       Impact factor: 13.501

View more
  20 in total

Review 1.  Neurobiological and immunogenetic aspects of narcolepsy: Implications for pharmacotherapy.

Authors:  Steven T Szabo; Michael J Thorpy; Geert Mayer; John H Peever; Thomas S Kilduff
Journal:  Sleep Med Rev       Date:  2018-11-08       Impact factor: 11.609

Review 2.  Circadian and sleep disorders in Parkinson's disease.

Authors:  Aleksandar Videnovic; Diego Golombek
Journal:  Exp Neurol       Date:  2012-08-23       Impact factor: 5.330

3.  Nigrostriatal Dopamine Acting on Globus Pallidus Regulates Sleep.

Authors:  Mei-Hong Qiu; Qiao-Ling Yao; Ramalingam Vetrivelan; Michael C Chen; Jun Lu
Journal:  Cereb Cortex       Date:  2014-10-14       Impact factor: 5.357

Review 4.  Challenges in the development of therapeutics for narcolepsy.

Authors:  Sarah Wurts Black; Akihiro Yamanaka; Thomas S Kilduff
Journal:  Prog Neurobiol       Date:  2015-12-23       Impact factor: 11.685

5.  Orexin neurons suppress narcolepsy via 2 distinct efferent pathways.

Authors:  Emi Hasegawa; Masashi Yanagisawa; Takeshi Sakurai; Michihiro Mieda
Journal:  J Clin Invest       Date:  2014-01-02       Impact factor: 14.808

6.  VTA dopaminergic neurons regulate ethologically relevant sleep-wake behaviors.

Authors:  Ada Eban-Rothschild; Gideon Rothschild; William J Giardino; Jeff R Jones; Luis de Lecea
Journal:  Nat Neurosci       Date:  2016-09-05       Impact factor: 24.884

7.  Trace Amine-Associated Receptor 1 Agonists as Narcolepsy Therapeutics.

Authors:  Sarah W Black; Michael D Schwartz; Tsui-Ming Chen; Marius C Hoener; Thomas S Kilduff
Journal:  Biol Psychiatry       Date:  2016-10-18       Impact factor: 13.382

8.  Dopamine D1 and D2 receptors mediate analgesic and hypnotic effects of l-tetrahydropalmatine in a mouse neuropathic pain model.

Authors:  Yuan-Yuan Liu; Tian-Xiao Wang; Ji-Chuan Zhou; Wei-Min Qu; Zhi-Li Huang
Journal:  Psychopharmacology (Berl)       Date:  2019-06-06       Impact factor: 4.530

9.  Almorexant promotes sleep and exacerbates cataplexy in a murine model of narcolepsy.

Authors:  Sarah Wurts Black; Stephen R Morairty; Simon P Fisher; Tsui-Ming Chen; Deepti R Warrier; Thomas S Kilduff
Journal:  Sleep       Date:  2013-03-01       Impact factor: 5.849

10.  Effects of orexin gene transfer in the dorsolateral pons in orexin knockout mice.

Authors:  Carlos Blanco-Centurion; Meng Liu; RodaRani Konadhode; Dheeraj Pelluru; Priyattam J Shiromani
Journal:  Sleep       Date:  2013-01-01       Impact factor: 5.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.